Parion Sciences

Executive Summary

Parion Sciences is a private, development-stage biopharmaceutical company headquartered in Durham, North Carolina, focused on restoring innate mucosal defense in the lung through epithelial sodium channel (ENaC) blockade. Founded in 2000, the company targets respiratory diseases with significant unmet need, such as cystic fibrosis, chronic bronchitis, and bronchiectasis. Its lead program is in Phase 2 development for cystic fibrosis, aiming to improve mucus clearance and lung function. Parion's technology addresses defective mucosal host defense, a common pathway in multiple chronic respiratory conditions. Despite a lengthy development timeline typical of small molecule therapies, the company has established a robust preclinical and clinical platform. The company remains private with no disclosed total funding, valuation, or employee range, and its stock is not publicly traded. As a Phase 2-stage entity, Parion faces typical development risks including trial recruitment, efficacy endpoints, and regulatory hurdles. However, the underlying science is well-supported by literature, and ENaC blockers represent a differentiated approach to respiratory disease. The company's progress in Phase 2 is a critical gating factor for future financing or partnership opportunities.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 clinical trial data readout for lead ENaC blocker in cystic fibrosis40% success
• Q2 2027Partnership or licensing deal for ENaC program in chronic bronchitis30% success
• Q3 2027IND filing for next-generation ENaC blocker50% success